Single, Dual and Triple Incretin Agonists Compared: Semaglutide, Tirzepatide, Retatrutide and the Limits of Cross-Trial Comparison

RESEARCH · RETATRUTIDE · SINGLE VS DUAL VS TRIPLE

Single, Dual and Triple Incretin Agonists Compared: Semaglutide, Tirzepatide, Retatrutide and the Limits of Cross-Trial Comparison

Three incretin-based research programmes are often discussed side by side: selective GLP-1 receptor agonists such as semaglutide (single target), dual GIP/GLP-1 agonists such as tirzepatide, and triple GIP/GLP-1/glucagon agonists such as retatrutide. PurixLab’s Retatrutide 10mg is the triple-agonist research material. Our earlier articles cover the phase 1–3 trial series, the glucagon-receptor mechanism and pharmacokinetics. This article compares the three programmes and, more importantly, explains why cross-trial comparisons are limited and where genuine head-to-head data do and do not exist. Retatrutide 10mg is supplied for laboratory research use only; the clinical results below describe regulated trials, not any product.

Three receptor strategies

The rationale is additive mechanism. Semaglutide acts at the GLP-1 receptor alone. Tirzepatide is a single peptide agonist at both GIP and GLP-1 receptors. Retatrutide (LY3437943) adds the glucagon receptor: its discovery paper describes balanced glucagon- and GLP-1-receptor activity with more GIP-receptor activity in vitro, and in obese mice glucagon-receptor-mediated energy expenditure added to the GIP- and GLP-1-driven reduction in calorie intake [1]. The hypothesis is that engaging glucagon signalling raises energy expenditure on top of appetite suppression, but a mechanism in mice is not an efficacy ranking in people.

What each programme reports in its own trials

Semaglutide (single). In STEP 1, once-weekly semaglutide 2.4 mg produced a mean weight change of −14.9% versus −2.4% with placebo over 68 weeks in adults with overweight or obesity without diabetes [2]. In STEP 2, in adults with type 2 diabetes, semaglutide 2.4 mg gave −9.6% versus −3.4% with placebo [3]. The SELECT cardiovascular outcomes trial of 17,604 patients with cardiovascular disease and overweight or obesity but without diabetes found a primary event in 6.5% on semaglutide versus 8.0% on placebo (hazard ratio 0.80) [4].

Tirzepatide (dual). In SURMOUNT-1, tirzepatide produced mean weight changes of −15.0%, −19.5% and −20.9% across its three doses versus −3.1% with placebo over 72 weeks [5]. In SURMOUNT-2 (obesity with type 2 diabetes), the 10 mg and 15 mg doses gave −12.8% and −14.7% versus −3.2% with placebo [6].

Retatrutide (triple). In the phase 2 obesity trial, mean weight change at 48 weeks was −24.2% in the 12 mg group versus −2.1% with placebo [7]. The phase 3 TRIUMPH-1 trial (2339 adults, 80 weeks) reported −17.6%, −23.7% and −25.0% across doses versus −3.9% with placebo [8], and TRIUMPH-2 (obesity with type 2 diabetes) reported −11.9%, −16.8% and −18.8% versus −5.1% with placebo [9].

Where head-to-head data actually exist

Direct, randomised comparisons are the exception, and they sit within, not across, these generations. SURPASS-2 randomly assigned 1879 patients with type 2 diabetes to tirzepatide or semaglutide 1 mg and found tirzepatide noninferior and superior on HbA1c, with greater weight reduction [10]. SURMOUNT-5 compared tirzepatide with semaglutide in obesity without diabetes and reported −20.2% versus −13.7% at 72 weeks [11]. For retatrutide, the only randomised active comparator so far is dulaglutide: in a phase 2 type 2 diabetes trial, retatrutide’s higher doses exceeded 1.5 mg dulaglutide on HbA1c and weight [12]. Crucially, no published randomised trial has compared retatrutide head-to-head with tirzepatide or with semaglutide as of 2026-10-17.

Why cross-trial comparison is limited

  • Different populations and durations. The trials differ in diabetes status, baseline BMI and length (for example 68, 72 and 80 weeks) [2,5,8], so placebo-subtracted percentages are not interchangeable.
  • Different placebo responses. Placebo weight change ranged from about −2.1% to −5.1% across these trials [7,9], which shifts any apparent between-drug gap.
  • Estimands differ. Trials use treatment-regimen or other estimands that handle discontinuation differently [5,6], affecting the reported number.
  • Dose and escalation differ. Each programme reports several doses with different escalation schemes [7,12].

Network meta-analyses try to bridge these gaps indirectly. One network meta-analysis of 58 trials and 24 214 participants ranked retatrutide first for weight loss (−22.10% versus placebo), ahead of tirzepatide (−19.28%) and CagriSema (−17.32%), while noting limited head-to-head evidence and overlapping confidence intervals [13]. A larger network meta-analysis of 262 trials rated the retatrutide estimate low to very low certainty because the agent is still emerging [14], and an updated systematic review reported numerically greater placebo-subtracted reductions with retatrutide (−22.1%) than tirzepatide (−19.0%) while stressing heterogeneity [15]. Indirect rankings are hypothesis-generating, not head-to-head proof.

Outcomes versus surrogates

A further asymmetry is cardiovascular-outcome evidence. Semaglutide has SELECT [4] and tirzepatide has SURPASS-CVOT, which found tirzepatide noninferior to dulaglutide for major cardiovascular events [16]. Retatrutide has no published cardiovascular outcomes trial yet; comparative animal work (for example on renal fibrosis) is mechanistic and not a clinical endpoint [17]. So the triple agonist shows the largest weight numbers in its own trials but the thinnest long-term outcome record.

What remains open

No randomised head-to-head trial pits retatrutide against tirzepatide or semaglutide; the comparisons above are indirect, with different populations, durations, placebo responses and estimands [13,14]. Until such trials and cardiovascular-outcome data are published, a “triple beats dual beats single” ranking remains a plausible hypothesis rather than a demonstrated fact. And none of this trial evidence, generated under medical supervision with pharmaceutical-grade product, describes the contents of any research vial.

Retatrutide 10mg at PurixLab

Retatrutide 10mg: a labelled lyophilized research vial with 10mg per vial, C$119 per vial (CAD, before tax), supplied for laboratory research only. Batch documentation is available on request. Product page: purixlab.com/product/retatrutide-10mg/.

PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.

In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge, and then you pay. There is no storefront or local pickup.

Payment is by Interac e-Transfer (instructions are shown at checkout) or by cryptocurrency through Plisio (Bitcoin, Ethereum, USDT and more): choose Plisio at checkout and you are sent to a secure Plisio payment page after placing the order. Current offers and any pack pricing are shown on the product page and in your cart; offers do not stack.

For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.

View Retatrutide 10mg

Questions or batch documentation requests: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ

References

  1. Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247.e9. PubMed 35985340 · doi:10.1016/j.cmet.2022.07.013
  2. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. PubMed 33567185 · doi:10.1056/NEJMoa2032183
  3. Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971-984. PubMed 33667417 · doi:10.1016/S0140-6736(21)00213-0
  4. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. PubMed 37952131 · doi:10.1056/NEJMoa2307563
  5. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. PubMed 35658024 · doi:10.1056/NEJMoa2206038
  6. Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402(10402):613-626. PubMed 37385275 · doi:10.1016/S0140-6736(23)01200-X
  7. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. PubMed 37366315 · doi:10.1056/NEJMoa2301972
  8. Jastreboff AM, Kaplan LM, Davies MJ, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. N Engl J Med. 2026 Sep (online ahead of print). PubMed 42814954 · doi:10.1056/NEJMoa2604169
  9. Bellido V, le Roux CW, Ekinci EI, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet. 2026;408(10563):1455-1472. PubMed 42810372 · doi:10.1016/S0140-6736(26)01861-1
  10. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503-515. PubMed 34170647 · doi:10.1056/NEJMoa2107519
  11. Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025;393(1):26-36. PubMed 40353578 · doi:10.1056/NEJMoa2416394
  12. Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529-544. PubMed 37385280 · doi:10.1016/S0140-6736(23)01053-X
  13. Chen D, Ma B, Sun H, et al. Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials. BMJ Med. 2026;5(1):e003026. PubMed 42688617 · PMC13536023 · doi:10.1136/bmjmed-2026-003026
  14. Nong K, Shi Q, Xie X, et al. Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis. BMJ. 2026;394:e372161. PubMed 42419792 · doi:10.1136/bmj-2026-372161
  15. Moiz A, Filion KB, Samuels AE, et al. Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic Review. Ann Intern Med. 2026 Sep (online ahead of print). PubMed 42673585 · doi:10.7326/ANNALS-25-05519
  16. Nicholls SJ, Pavo I, Bhatt DL, et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. N Engl J Med. 2025;393(24):2409-2420. PubMed 41406444 · doi:10.1056/NEJMoa2505928
  17. Ding M, Li X, Wei Y, et al. Comparative effects of semaglutide tirzepatide and retatrutide on renal fibrosis in UUO and aged mice. iScience. 2026;29(9):117174. PubMed 42630988 · PMC13495082 · doi:10.1016/j.isci.2026.117174

Leave a Comment

Your email address will not be published. Required fields are marked *